Genetic susceptibility to Schizophrenia: Role of dopaminergic pathway gene polymorphisms

Pharmacogenomics

Volumn 10, Issue 2, 2009, Pages 277-291

  Gupta, Meenal ^a   Chauhan, Chitra ^a   Bhatnagar, Pallav ^a   Gupta, Simone ^a   Grover, Sandeep ^a   Singh, Prashant K ^a   Purushottam, Meera ^b   Mukherjee, Odity ^b   Jain, Sanjeev ^b   Brahmachari, Samir K ^a   Kukreti, Ritushree ^a  

^a CSIR INSTITUTE OF GENOMICS AND INTEGRATIVE BIOLOGY   (India)

^b NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

Association study; BDNF; COMT; DRD2; Gene gene interactions; Schizophrenia

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CATECHOL METHYLTRANSFERASE; DOPAMINE 2 RECEPTOR; NEUROLEPTIC AGENT; DOPAMINE 3 RECEPTOR; DRD3 PROTEIN, HUMAN;

ADULT; ANALYTICAL ERROR; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; FEMALE; GENE FREQUENCY; GENE INTERACTION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; INDIA; MAJOR CLINICAL STUDY; MALE; PREDICTION; RISK FACTOR; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; AMINO ACID SUBSTITUTION; CASE CONTROL STUDY; EXON; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENETICS; REFERENCE VALUE;

ADULT; AMINO ACID SUBSTITUTION; BRAIN-DERIVED NEUROTROPHIC FACTOR; CASE-CONTROL STUDIES; CATECHOL O-METHYLTRANSFERASE; EXONS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; INDIA; MALE; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, DOPAMINE D3; REFERENCE VALUES; SCHIZOPHRENIA; YOUNG ADULT;

EID: 65549159155     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.10.2.277     Document Type: Article

References (73)

1. Muller DJ, Luca VD, Kennedy JL: Overview: towards individualized treatment in schizophrenia. Drug Dev. Res. 60, 75-94 (2003).
2. Verma R, Mukerji M, Grover D et al.: MLC1 gene is associated with schizophrenia and bipolar disorder in southern India. Biol. Psychiatry 58, 16-22 (2005).
3. Seeman P: Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1, 133-152 (1987).
4. Gupta S, Jain S, Brahmachari SK, Kukreti R: Pharmacogenomics: a path to predictive medicine for schizophrenia. Pharmacogenomics 7, 31-47 (2006).
5. Arinami T, Gao M, Hamaguchi H, Toru M: A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum. Mol. Genet. 6, 577-582 (1997).
6. Serretti A, Lattuada E, Lorenzi C, Lilli R, Smeraldi E: Dopamine receptor D2 Ser/Cys 311 variant is associated with delusion and disorganization symptomatology in major psychoses. Mol. Psychiatry 5, 270-274 (2000).
7. Hanninen K, Katila H, Kampman O et al.: Association between the C957T polymorphism of the dopamine D2 receptor gene and schizophrenia. Neurosci. Lett. 407, 195-198 (2006).
8. Vijayan NN, Bhaskaran S, Koshy IV et al.: Association of dopamine receptor polymorphisms with schizophrenia and antipsychotic response in a South Indian population. Behav. Brain Funct. 3, 34 (2007).
9. Verga M, Macciardi F, Pedrini S, Cohen S, Smeraldi E: No association of the Ser/Cys311 DRD2 molecular variant with schizophrenia using a classical case control study and the haplotype relative risk. Schizophr. Res. 25, 117-121 (1997).
10. Hori H, Ohmori O, Shinkai T, Kojima H, Nakamura J: Association analysis between two functional dopamine D2 receptor gene polymorphisms and schizophrenia. Am. J. Med. Genet. 105, 176-178 (2001).
11. Glatt SJ, Faraone SV, Tsuang MT: DRD2 -141C insertion/deletion polymorphism is not associated with schizophrenia: results of a meta-analysis. Am. J. Med. Genet. B Neuropsychiatr. Genet. 128, 21-23 (2004).
12. Sanders AR, Duan J, Levinson DF et al.: No significant association of 14 candidate genes with schizophrenia in a large European ancestry sample: implications for psychiatric genetics. Am. J. Psychiatry 165, 497-506 (2008).
13. Zhang Y, Bertolino A, Fazio L et al.: Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory. Proc. Natl Acad. Sci. USA 104, 20552-20557 (2007).
14. Kukreti R, Tripathi S, Bhatnagar P et al.: Association of DRD2 gene variant with schizophrenia. Netirosci. Lett. 392, 68-71 (2006).
15. Glatt SJ, Jonsson EG: The Cys allele of the DRD2 Ser311Cys polymorphism has a dominant effect on risk for schizophrenia: evidence from fixed- and random-effects meta-analyses. Am. J Med. Genet. B Neuropsychiatr. Genet. 141, 149-154 (2006).
16. Tunbridge EM, Harrison PJ, Weinberger DR: Catechol-O-methyltransferase, cognition, and psychosis: Val158Met and beyond. Biol. Psychiatry 60, 141-151 (2006).
17. Owen MJ, Williams NM, O'Donovan MC: The molecular genetics of schizophrenia: new findings promise new insights. Mol. Psychiatry 9, 14-27 (2004).
18. Williams NM, Owen MJ: Genetic abnormalities of chromosome 22 and the development of psychosis. Curr. Psychiatry Rep. 6, 176-182 (2004).
19. Shprintzen RJ, Goldberg R, Golding-Kushner KJ, Marion RW: Late-onset psychosis in the velo-cardio-facial syndrome. Am. J Med. Genet. 42, 141-142 (1992).
20. Gothelf D, Schaer M, Eliez S: Genes, brain development and psychiatric phenotypes in velo-cardio-facial syndrome. Dev. Disabil. Res. Rev. 14, 59-68 (2008).
21. Lotta, T, Vidgren J, Tilgmann C et al.: Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 34, 4202-4210 (1995).
22. Chen J, Lipska BK, Halim N et al.: Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain, Am. J. Hum. Genet. 75, 807-821 (2004).
23. Palmatier MA, Kang AM, Kidd KK: Global variation in the frequencies of functionally different catechol-O-methyltransferase alleles. Biol. Psychiatry 46, 557-567 (1999).
24. Chen X, Wang X, O'Neill AF, Walsh D, Kendler KS: Variants in the catechol-O- methyltransferase (COMT) gene are associated with schizophrenia in Irish high-density families. Mol. Psychiatry 9, 962-967 (2004).
25. Handoko HY, Nyholt DR, Hayward NK et al.: Separate and interacting effects within the catechol-O-methyltransferase (COMT) are associated with schizophrenia. Mol. Psychiatry 10, 589-597 (2005).
26. Abdolmaleky HM, Cheng KH, Faraone SV et al.: Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder. Hum. Mol. Genet. 15, 3132-3145 (2006).
27. Pelayo-Terán JM, Crespo-Facorro B, Carrasco-Marín E: Catechol-O-methyltransferase Val158Met polymorphism and clinical characteristics in first episode non-affective psychosis. Am. J. Med. Genet. B Neuropsychiatr. Genet. 147B, 550-556 (2008).
28. Sernwal P, Pfasad S, Varma PG, Bhagwat AM, Deshpande SN, Thelma BK: Candidate gene polymorphisms among North Indians and their association with schizophrenia in a case-control study. J. Genet. 81, 65-71 (2002).
29. Glatt SJ, Faraone SV, Tsuang MT: Association between a functional catechol O-methyltransferase gene polymorphism, and schizophrenia: meta-analysis of case-control and family-based studies. Am. J. Psychiatry 160, 469-476 (2003).
30. Fan JB, Zhang CS, Gu NF et al.: Catechol-O-methyltransferase gene Val/Met functional polymorphism and risk of schizophrenia: 2 large-scale association study plus meta-analysis. Biol. Psychiatry 57, 139-144 (2005).
31. Munafo MR, Bowes L, Clark TG, Flint J: Lack of association of the COMT (Val158/108 Met) gene and schizophrenia: a meta-analysis of case-control studies. Mol. Psychiatry 10, 765-770 (2005).
32. Nunokawa A, Watanabe Y, Muratake T, Kaneko N, Koizumi M, Someya T: No associations exist between five functional polymorphisms in the catechol-O-methyltransferase gene and schizophrenia in a Japanese population. Neurosci. Res. 58, 291-296 (2007).
33. Shifman S, Bronstein M, Sternfeld M et al.: A highly significant association between a COMT haplotype and schizophrenia. Am. J. Hum. Genet. 71, 1296-1302 (2002).
34. Lee SG, Joo Y, Kim B et al.: Association of Ala72Ser polymorphism. with COMT enzyme activity and the risk of schizophrenia in Koreans. Hum. Genet. 116, 319-328 (2005).
35. Meyer-Lindenberg A, Nichols T, Callicott JH et al.: Impact of complex genetic variation in COMT on human brain function. Mol. Psychiatry 11, 867-877 (2006).
36. Bray NJ, Buckland PR, Williams NM et al.: A haplotype implicated in schizophrenia susceptibility is associated with reduced COMT expression in human brain. Am. J. Hum. Genet. 73, 152-161 (2003).
37. Angelucci F, Brene S, Mathe AA: BDNF in schizophrenia, depression and corresponding animal models. Mol. Psychiatry 10, 345-352 (2005).
38. Galderisi S, Maj M, Kirkpatrick B et al.: COMT Val(158)Met and BDNF C(270)T polymorphisms in schizophrenia: a case-control study. Schizophr. Res. 73, 27-30 (2005).
39. Dluzen DE, Gao X, Story GM, Anderson LI, Kucera J, Walro JM: Evaluation of nigrostriatal dopaminergic function in adult +/+ and +/- BDNF mutant mice. Exp. Neurol. 170, 121-128 (2001).
40. Durany N, Michel T, Zochling R et al.: Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses. Schizophr. Res. 52, 79-86 (2001).
41. Egan MF, Weinberger DR, Lu B: Schizophrenia, III: brain-derived neurotropic factor and genetic risk. Am. J. Psychiatry 160, 1242 (2003).
42. Neves-Pereira M, Cheung JK, Pasdar A et al.: BDNF gene is a risk factor for schizophrenia in a Scottish population. Mol. Psychiatry 10, 208-212 (2005).
43. Watanabe Y, Muratake T, Kaneko N, Nunokawa A, Someya T. No association between the brain-derived neurotrophic factor gene and schizophrenia in a Japanese population. Schizophr. Res. 84, 29-35 (2006).
44. Naoe Y, Shinka-i T, Hori H et al.: No association between the brain-derived neurdtrophic factor (BDNF) Val66Met polymorphism and schizophrenia in Asian populations: Evidence from a case-control study and meta-analysis. Neurosci. Lett. 415, 108-112 (2007).
45. Cloninger CR: Multilocus genetics of schizophrenia. Curr. Opin. Psychiatry 10, 5-10 (1997).
46. Moore JH, Williams SM: New strategies for identifying gene-gene interactions in hypertension. Ann. Med. 34, 88-95 (2002).
47. Ritchie MD, Hahn LW, Roodi N et al.: Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. Am. J. Hum. Genet. 69, 138-147 (2001).
48. Cho YM, Ritchie MD, Moore JH et al.: Multifactof-dimensionality reduction shows a two-locus interaction associated with Type 2 diabetes mellitus. Diabetologia 47, 549-554 (2004).
49. Xu J, Lowey J, Wiklund F et al.: The interaction of four genes in the inflammation pathway significantly predicts prostate cancer risk. Cancer Epidemiol. Biomarkers Prev. 14, 2563-2568 (2005).
50. Motsinger AA, Brassat D, Caillier SJ et al.: Complex gene-gene interactions in multiple sclerosis: a multifactofial approach reveals associations with inflammatory genes. Neurogenetics 8, 11-20 (2007).
51. Wing JK, Babor T, Brugha T et al.: SCAN. Schedules for clinical assessment in neuropsychiarry. Arch. Gen. Psychiatry 47, 589-593 (1990).
52. McGuffin P, Farmer A, Harvey I: A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system. Arch. Gen. Psychiatry 48, 764-770 (1991).
53. Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16, 1215 (1988).
54. Nyholt DR: A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am. J. Hum. Genet. 74, 765-769 (2004).
55. Gordon D, Finch SJ, Nothnagel M, Ott J: Power and sample size calculations for case-control genetic association tests when errors are present: application to single nucleotide polymorphisms. Hum. Hered. 54, 22-33 (2002).
56. Gordon D, Levenstien MA, Finch SJ, Ott J: Errors and linkage disequilibrium interact multiplicatively when computing sample sizes for genetic case-control association studies. Pac. Symp. Biocomput. 490-501 (2003).
57. Barrett JC, Fry B, Mallet J, Daly MJ: Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21, 263-265 (2005).
58. Hahn LW, Ritchie MD, Moore JH: Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions. Bioinformatics 19, 376-382 (2003).
59. Kim SH, Jeong HH, Cho BY et al.: Association of four-locus gene interaction with aspirin-intolerant asthma in Korean asthmatics. J. Clin. Immunol. 28, 336-342 (2008).
60. Iida K, Akashu H: A test for translational selection at 'silent' sites in the human genome: base composition comparisons in alternatively spliced genes. Gene 261, 93-105 (2000).
61. Mo GH, Liao DL, Lai IC et al.: Support for an association of the C939T polymorphism in the human DRD2 gene with tardive dyskinesia in schizophrenia. Schizophr. Res. 97(1-3), 302-304 (2007).
62. Tanaka Y, Sasaki M, Shiina H et al.: Catechol-O-methyltransferase gene polymorphisms in benign prostatic hyperplasia and sporadic prostate cancer. Cancer Epidemiol. Biomarkers Prev. 15, 238-244 (2006).
63. Rothe C, Koszycki D, Bradwejn J et al.: Association of the Va1158Met catechol O-methyltranskrase genetic polymorphism with panic disorder. Neuropsychopharmacology 31, 2237-2242 (2006).
64. Voutilainen S, Tuomainen TP, Korhonen M et al.: Functional COMTVal158Met polymorphism, risk of acute coronary events and serum homocysteine: the kuopio ischaemic heart disease risk factor study. PLoS ONE 2, E181 (2007).
65. Pooley EC, Fineberg N, Harrison PJ: The met(158) allele of catechol-O-methyltransferase (COMT) is associated with obsessive-compulsive disorder in men: case-control study and meta-analysis. Mol. Psychiatry 12, 556-561 (2007).
66. Shifman S, Bronstein M, Sternfeld M et al.: COMT: a common susceptibility gene in bipolar disorder and schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 128, 61-64 (2004).
67. Egan MF, Goldberg TE, Kolachana BS et al.: Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc. Natl Acad. Sci. USA 98, 6917-6922 (2001).
68. Woodward ND, Jayathilake K, Meltzer HY: COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia. Schizophr. Res. 90, 86-96 (2007).
69. Ohnishi T, Hashimoto R, Mori T et al.: The association between the Val158Met polymorphism of the catechol-O-methyl transferase gene and morphological abnormalities of the brain in chronic schizophrenia. Brain 129, 399-410 (2006).
70. Gupta M, Bhatnagar P, Grover S et al.: Association studies of catechol-O-methyl transferase (COMT) gene with schizophrenia and response to antipsychotic treatment. Pharmacogenomics (2009) (In press).
71. Numata S, Ueno S, Iga J et al.: Interaction between catechol-O-methyltransferase (COMT) Val108/158Met and brain-derived neurotrophic factor (BDNF) Val66Met polymorphisms in age at onset and clinical symptoms in schizophrenia. J. Neural Transm. 114, 255-259 (2007).
72. Xu H, Kellendonk CB, Simpson EH et al.: DRD2 C957T polymorphism interacts with the COMTVal158Met polymorphism in human working memory ability. Schizophr. Res. 90, 104-107 (2007).
73. Gosso MF, de Geus EJ, Polderman TJ, Boomsma DI, Heutink P, Posthuma D: Catechol O-methyl transferase and dopamine D2 receptor gene polymorphisms: evidence of positive heterosis and gene-gene interaction on working memory functioning. Eur. J. Hum. Genet. 16, 1075-1082 (2008).